Prostate Cancer
The clinical research activity of Azienda Provinciale Per I Servizi Sanitari is centered on prostate cancer, with particular attention to metastatic castration-resistant prostate cancer and disease progression after androgen-receptor signaling inhibitor treatment and olaparib.
- mCRPC
- Androgen-receptor signaling inhibitor resistance
- Olaparib after progression
Its funded research also includes comparison of docetaxel-based treatment strategies, including combinations with prednisone and carboplatin, in advanced prostate cancer.
Systemic Therapy in Advanced Urologic Oncology
Interest extends to systemic anticancer therapy for advanced urologic malignancies, with emphasis on treatment sequencing after prior targeted and hormonal therapy.
- Docetaxel-based regimens
- Carboplatin combination therapy
- Post-ARSI treatment
The sponsor’s clinical focus is on therapeutic options used when prostate cancer becomes resistant to earlier lines of treatment.
Oncology Care Network
The trial activity involves a multi-site oncology network across Italy, reflecting clinical involvement in coordinated cancer care and patient access to specialized treatment settings.
- Collaborating research sites
- Hospital-based oncology
- Italian cancer research
Within this setting, the sponsor contributes to research in advanced-stage disease management through studies conducted in clinical care environments.
